Codexis to Showcase Innovations at Major Healthcare Events
Codexis, Inc. (NASDAQ: CDXS), a leader in enzyme engineering, has announced its participation in two significant upcoming investor conferences. These events will serve as excellent opportunities to highlight their innovative technologies and advancements in the industry.
The Cantor Global Healthcare Conference
During the Cantor Global Healthcare Conference, which is scheduled for a Tuesday, Codexis management will participate in a fireside chat. This discussion will focus on their latest innovations and business strategies.
The Craig-Hallum Bioprocessing Conference
At the Craig-Hallum Bioprocessing Conference, Codexis management will also engage in a fireside chat. This session will provide valuable insights into the company’s forward-thinking initiatives as they continue to advance the field of enzyme engineering.
Webcast Availability
Investors and stakeholders can tune in to a live webcast of the fireside chat at the Cantor conference, which will be available in the Investor Relations section of Codexis’s website. Furthermore, recordings of both conferences will be archived and accessible for at least 90 days, ensuring that important information and discussions reach a broader audience.
About Codexis
Codexis is a pioneer in enzyme technology, utilizing its proprietary CodeEvolver technology platform to develop and enhance innovative enzymes and proteins. These advancements tackle critical challenges in the production of small molecule pharmaceuticals and other applications, especially in nucleic acid synthesis. Currently, Codexis is advancing its ECO Synthesis™ platform, which aims to efficiently produce RNAi therapeutics through an enzymatic approach, promising higher yields and a reduced environmental footprint.
Recent Developments and Future Insights
With a strong emphasis on environmental sustainability and efficiency, Codexis is committed to continuously innovating and refining its enzyme solutions. Their dedication to improving production efficiency, along with ongoing enhancements in manufacturing practices, underscores their commitment to supporting future pharmaceutical advancements. Codexis's unique enzymatic processes contribute to significant reductions in energy consumption and waste generation, establishing them as a key player in the biotech industry.
For More Information
If you have any questions or need further insights, please contact Carrie McKim, the Investor Contact, at (336) 608-9706 or via email at ir@codexis.com. For media inquiries, please reach out to Lauren Musto at (650) 421-8205 or media@codexis.com.
Frequently Asked Questions
What is Codexis, Inc. known for?
Codexis, Inc. specializes in enzyme engineering and technological innovations that support the manufacturing of pharmaceuticals and other biotechnology applications.
When will Codexis participate in the healthcare conferences?
Codexis will take part in the Cantor Global Healthcare Conference on September 17, followed by the Craig-Hallum Bioprocessing Conference on September 19.
How can investors access the webcast?
Investors can access the webcast of the fireside chat in the Investor Relations section of the Codexis website.
What are Codexis's recent technological advancements?
Codexis is focused on enhancing its enzyme production capabilities and developing the ECO Synthesis platform for RNAi therapeutics, with an emphasis on sustainability and efficiency.
Who can I contact for more information about Codexis?
For inquiries related to investors, you can contact Carrie McKim, and for media questions, please reach out to Lauren Musto using the provided emails.
